Next 10 |
The pooled analysis included data from 4 i nternational clinical trials spanning a n array of hard-to-treat indications including skin, head & neck, and oral cavity. Initial response data demonstrated an overall response rate of almost 100% in tre...
2024-05-21 10:00:22 ET Jason Bednar from Piper Sandler issued a price target of $7.00 for DRTS on 2024-05-21 08:51:00. The adjusted price target was set to $7.00. At the time of the announcement, DRTS was trading at $2.91. The overall price target consensus is at $12.00 ...
JERUSALEM, May 21, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that CFO Raphi Levy will present a corporate overview an...
2024-05-20 16:37:42 ET More on Alpha Tau Medical Seeking Alpha’s Quant Rating on Alpha Tau Medical Historical earnings data for Alpha Tau Medical Financial information for Alpha Tau Medical Read the full article on Seeking Alpha For further det...
- Presented preclinical data demonstrating abscopal immune effect in pancreatic murine tumor models at ESTRO 2024 Congress in Glasgow - - First patient with liver metastases treated in a feasibility and safety study of Alpha DaRT at the McGill University Health Center in Montreal, C...
JERUSALEM, May 13, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that its first patient with liver cancer metastases has been t...
- Initial data demonstrates significant reduction in distant pancreatic cancer tumor growth rate starting from three weeks after first tumor is treated with Alpha DaRT alone - Effect seen across both Panc02 and KPC tumor models - JERUSALEM, May 06, 2024 (GLOBE NEWSWIRE) -- Alpha T...
JERUSALEM, May 01, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that CFO Raphi Levy will present at the following investor con...
JERUSALEM, March 25, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that CFO Raphi Levy will present a corporate overview ...
2024-03-07 17:37:55 ET More on Alpha Tau Medical Seeking Alpha’s Quant Rating on Alpha Tau Medical Historical earnings data for Alpha Tau Medical Financial information for Alpha Tau Medical Read the full article on Seeking Alpha For further det...
News, Short Squeeze, Breakout and More Instantly...
Alpha Tau Medical Ltd. Company Name:
DRTS Stock Symbol:
NASDAQ Market:
Alpha Tau Medical Ltd. Website:
The pooled analysis included data from 4 i nternational clinical trials spanning a n array of hard-to-treat indications including skin, head & neck, and oral cavity. Initial response data demonstrated an overall response rate of almost 100% in tre...
2024-05-21 10:00:22 ET Jason Bednar from Piper Sandler issued a price target of $7.00 for DRTS on 2024-05-21 08:51:00. The adjusted price target was set to $7.00. At the time of the announcement, DRTS was trading at $2.91. The overall price target consensus is at $12.00 ...
JERUSALEM, May 21, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that CFO Raphi Levy will present a corporate overview an...